Welcome to LookChem.com Sign In|Join Free
  • or
N-[2-(allyloxy)-5-chlorophenyl]-N'-[6-(3-butenyloxy)-5-cyano-2-pyrazinyl]urea is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

851025-75-7

Post Buying Request

851025-75-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

851025-75-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 851025-75-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,1,0,2 and 5 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 851025-75:
(8*8)+(7*5)+(6*1)+(5*0)+(4*2)+(3*5)+(2*7)+(1*5)=147
147 % 10 = 7
So 851025-75-7 is a valid CAS Registry Number.

851025-75-7Downstream Products

851025-75-7Relevant academic research and scientific papers

Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors

Tao, Zhi-Fu,Wang, Le,Stewart, Kent D.,Chen, Zehan,Gu, Wendy,Bui, Mai-Ha,Merta, Philip,Zhang, Haiying,Kovar, Peter,Johnson, Eric,Park, Chang,Judge, Russell,Rosenberg, Saul,Sowin, Thomas,Lin, Nan-Horng

, p. 1514 - 1527 (2008/02/02)

Based on the crystallographic analysis of a urea-checkpoint kinase 1 (Chk1) complex and molecular modeling, a class of macrocyclic Chk1 inhibitors were designed and their biological activities were evaluated. An efficient synthetic methodology for macrocyclic ureas was developed with Grubbs metathesis macrocyclization as the key step. The structure-activity relationship studies demonstrated that the macrocyclization retains full Chk1 inhibition activity and that the 4-position of the phenyl ring can tolerate a wide variety of substituents. These novel Chk1 inhibitors exhibit excellent selectivity over a panel of more than 70 kinases. Compounds 5b, 5c, 5f, 15, 16d, 17g, 17h, 17k, 18d, and 22 were identified as ideal Chk1 inhibitors, which showed little or no single-agent activity but significantly potentiate the cytotoxicities of the DNA-damaging antitumor agents doxorubicin and camptothecin. These novel Chk1 inhibitors abrogate the doxorubicin-induced G2 and camptothecin-induced S checkpoint arrests, confirming that their potent biological activities are mechanism-based through Chk1 inhibition.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 851025-75-7